At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 343 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
AMG 301 5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
In Brief
A Phase 2 clinical trial evaluating Placebo and AMG 301 for Chronic Migraine or Episodic Migraine. Completed, enrolled 343 participants across 49 sites in 8 countries.
Detailed Summary
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine or Episodic Migraine
CountriesAustria, Canada, Czechia, Denmark, Finland, Germany, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionOct 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedAug 3, 2017
Enrollment StartSep 6, 2017
Primary CompletionOct 16, 2018
Study CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.9 years ago
Interventions
Placebodrug
Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
AMG 301drug
AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.